Dr. Tim Henkel Joins Venatorx Pharmaceuticals As Chief Medical Officer Malvern, PA, January 1, 2015 — Dr. Tim Henkel has joined Venatorx Pharmaceuticals as Chief Medical Officer. Dr. Henkel has spent 20 years in the biopharmaceutical industry developing antibacterial, antifungal, antiviral, immunomodulatory and oncology drugs. He has successfully developed biologics, small molecules and natural products...
Author: @admin
James G. Murphy Joins VenatoRx As Chief Financial Officer
James G. Murphy Joins VenatoRx As Chief Financial Officer Malvern, PA, November 13, 2014 — Jim Murphy has joined VenatoRx as Chief Financial Officer. Jim has over 25 years’ experience as a senior financial executive in public and privately held companies in the life sciences and the media and technology industries. He has served as...
VenatoRx Awarded NIH RO1 Grant
VenatoRx has been awarded an NIH R01 Grant for novel approaches to address biodefense-related infections. The company may receive up to $6M of funding under the grant. READ FULL TEXT
Venatorx Pharmaceuticals Awarded NIH RO1 Grant
Venatorx Pharmaceuticals has been awarded an NIH R01 Grant for novel approaches to address biodefense-related infections. The company may receive up to $6M of funding under the grant. READ FULL TEXT
VenatoRx Completes Series A Financing
VenatoRx has completed a Series A financing round of approximately $3.5M from private investors to complement its other sources of funding and help advance its novel discovery and development programs. READ FULL TEXT
Venatorx Pharmaceuticals Completes Series A Financing
Venatorx Pharmaceuticals has completed a Series A financing round of approximately $3.5M from private investors to complement its other sources of funding and help advance its novel discovery and development programs. READ FULL TEXT
VenatoRx awarded funding from the Wellcome Trust
VenatoRx received an investment of $8.9M from the Wellcome Trust Translation Fund for the “Development of novel small molecules for the treatment of antibiotic resistant bacterial infections. READ FULL TEXT
Venatorx Pharmaceuticals awarded funding from the Wellcome Trust
Venatorx Pharmaceuticals announced that it has received an investment of $8.9M from the Wellcome Trust Translation Fund for the “Development of novel small molecules for the treatment of antibiotic resistant bacterial infections.” Venatorx is developing new antibacterial therapeutic products to address multi-drug resistant gram negative bacteria, including resistant E. coli, K. pneumoniae, and P. aeruginosa, important...
VenatoRx Awarded NIH Contract
VenatoRx was elected to execute a research and development contract around proprietary compounds that address resistant NIAID Category A, B, and C pathogens. The contract award is for up to $21.2M. READ FULL TEXT
CDC Releases Report on ANTIBIOTIC RESISTANCE THREATS in the United States
In the report, Carbapenem Resistant Enterobacteriaceae was classified as an Urgent treat. READ FULL TEXT